The landscape of the American healthcare industry is undergoing a seismic shift as major corporations and federal regulators grapple with the complexities of vertical integration, technological advancement, and price transparency. CVS Health, a cornerstone of the domestic healthcare sector, recently announced a definitive plan to split its sprawling operations into two independent, publicly traded companies by 2028. This decision comes at a time of heightened scrutiny from lawmakers and a cooling of investor enthusiasm for the vertically integrated model that has defined the company for nearly a decade. The move, characterized by some industry analysts as a tactical retreat from the "one-stop-shop" healthcare vision, reflects broader tensions within the industry regarding market dominance, patient costs, and the role of middleman entities such as Pharmacy Benefit Managers (PBMs).
The CVS Health Bifurcation: A Strategic Realignment
The restructuring plan outlined by CVS Health involves a clean break between its insurance and services arms and its traditional retail operations. The first entity, which will retain the CVS Health name, is set to be a powerhouse of healthcare services and insurance. This business will house Aetna, the health insurance giant acquired in 2018; CVS Caremark, one of the nation’s largest PBMs; CVS Specialty; and the company’s recent multibillion-dollar acquisitions, Oak Street Health and Signify Health. David Joyner, the current chairman and CEO of CVS Health, is slated to lead this organization, which will focus on integrated care delivery and insurance management.
The second entity, to be branded as CVS Pharmacy, will operate as a national retail pharmacy and community healthcare provider. This company will manage approximately 9,000 retail locations across the United States, alongside the company’s mail-order pharmacy operations, MinuteClinic locations, and the Health100 technology services business. Prem Shah, currently the group president of CVS Health, has been tapped to lead this retail-focused enterprise.
While CVS leadership framed the split as a way to unlock shareholder value and provide greater focus for each business unit, critics and industry observers suggest the move is a defensive response to mounting political and regulatory pressure. The decision follows years of criticism regarding the inherent conflicts of interest that arise when a single corporation owns the insurance provider (Aetna), the entity that negotiates drug prices (Caremark), and the pharmacy that dispenses the medication (CVS Pharmacy). Mark Cuban, co-founder of Cost Plus Drugs and a vocal critic of the PBM industry, described the restructuring as "brilliant financial engineering," suggesting that the move is designed more to insulate profit margins from regulatory interference than to fundamentally lower costs for consumers.
Historical Context and the End of the Vertical Integration Era
To understand the magnitude of this split, one must look back at the 2018 acquisition of Aetna by CVS Health for approximately $69 billion. At the time, the deal was heralded as a revolutionary step toward "vertical integration," a strategy intended to control every aspect of the patient journey to drive down costs and improve outcomes. By owning the payer, the provider, and the pharmacy, CVS Health argued it could eliminate inefficiencies and provide a seamless experience for members.
However, the reality of the last six years has proven more complicated. The integration of Aetna, followed by the $10.6 billion acquisition of Oak Street Health and the $8 billion purchase of Signify Health, saddled the company with significant debt and operational complexities. Furthermore, the vertical integration model became a lightning rod for federal scrutiny. The Federal Trade Commission (FTC) and various congressional committees have spent much of the last two years investigating PBM practices, specifically how they may inflate drug prices and disadvantage independent pharmacies.
The proposed "Break Up Big Medicine Act," introduced by a bipartisan coalition including Senators Elizabeth Warren and Josh Hawley, serves as the legislative backdrop for this restructuring. The bill aims to prohibit PBMs from owning pharmacies and vice-versa, a direct hit to the CVS-Caremark-Aetna triad. By proactively splitting the company, CVS Health may be attempting to stay ahead of potential federal mandates that could force a less favorable divestiture in the future.
The Role of Artificial Intelligence in Healthcare Operations
As CVS navigates its corporate divorce, the broader healthcare industry is simultaneously wrestling with the integration of artificial intelligence (AI). A recent report by Bessemer Venture Partners, titled the 2026 Healthcare AI ROI Scorecard, provides a sobering look at the current state of AI adoption in the sector. While the hype surrounding generative AI has been immense, the actual return on investment (ROI) remains concentrated in administrative rather than clinical areas.
According to the survey of healthcare executives, the highest ROI for AI tools is currently found in revenue cycle management (RCM). These tools are being used to automate billing, predict claim denials, and streamline the complex interaction between providers and insurers. In these back-office functions, the objective nature of the data allows AI to perform with high efficiency and low risk.
In contrast, clinical AI adoption faces a significant trust deficit. The Bessemer report revealed that only 46% of healthcare executives trust AI-generated tools to support clinical decision-making. More tellingly, 77% of clinicians report overriding AI suggestions more than half the time. This skepticism stems from concerns over "hallucinations" in large language models and the high stakes of medical errors. For AI to become a staple of clinical practice, developers must move beyond general-purpose models and provide transparent, evidence-based tools that can withstand the rigors of medical peer review.
Regulatory Evolution: The FDA and Generative AI
The regulatory framework for AI is also in a state of flux. The Food and Drug Administration (FDA) is preparing to publish a final rule regarding the regulation of generative AI-enabled medical devices. This follows a discussion paper released earlier this year that drew more than 300 comments from stakeholders ranging from tech giants to patient advocacy groups.
Rick Abramson, director of the FDA’s Digital Health Center of Excellence, recently suggested that the agency may move toward a "physician competency" model for evaluating generative AI. Traditionally, the FDA has evaluated "Software as a Medical Device" (SaMD) based on safety and efficacy through static clinical trials. However, because generative AI is dynamic and learns over time, a static evaluation may be insufficient.
The proposed shift would treat AI more like a medical professional who must undergo routine competency assessments. This would involve continuous monitoring of the AI’s outputs to ensure it remains accurate and safe as it processes new data. This represents a fundamental departure from traditional medical device regulation and highlights the challenges regulators face in keeping pace with rapid technological advancement.
FTC Enforcement and the Push for Price Transparency
While the FDA focuses on technology, the Federal Trade Commission (FTC) is intensifying its focus on the financial transparency of healthcare organizations. Last month, the FTC issued warning letters to 24 healthcare organizations regarding inadequate price transparency. These letters serve as a formal notice that the organizations are in violation of federal rules designed to empower consumers to shop for healthcare services based on cost and quality.
The push for price transparency began in earnest with the 2021 Hospital Price Transparency Rule, which required hospitals to post their standard charges online in a machine-readable format. However, compliance has been inconsistent. The FTC’s recent actions signal a transition from a period of education to a period of enforcement. Industry experts have likened these warning letters to "yellow cards" in a soccer match—a final warning before more severe financial penalties or legal actions are taken.
The demand for transparency is a direct response to the "black box" pricing models that have dominated American healthcare for decades. By forcing organizations to reveal the negotiated rates between insurers and providers, regulators hope to foster a more competitive market that ultimately lowers out-of-pocket costs for patients.
Broader Impact and Future Outlook
The restructuring of CVS Health and the tightening of regulatory oversight across AI and pricing represent a new chapter in the evolution of the U.S. healthcare system. The era of unchecked vertical expansion appears to be giving way to a period of decentralization and increased accountability.
For CVS Health, the 2028 split will be a test of whether its constituent parts are stronger than the whole. The insurance and services business will need to prove it can maintain its market share without the direct support of a massive retail footprint, while the retail pharmacy business must find a way to remain profitable in an era of declining reimbursement rates and increased competition from digital-first pharmacies like Amazon Pharmacy and Cost Plus Drugs.
For the industry at large, the message from regulators is clear: market dominance will no longer be shielded from scrutiny by the complexity of corporate structures. Whether through the breakup of large entities, the rigorous evaluation of new technologies, or the enforcement of transparency rules, the focus is shifting toward a model that prioritizes consumer choice and market competition. As these changes unfold, the primary challenge for healthcare leaders will be balancing the need for corporate profitability with the growing public and political demand for a more affordable and transparent healthcare system.
